Balance-sheet StrengthMinimal debt and a large equity base (~SEK 4.4bn) materially lower financial risk and provide durable optionality. This capital buffer supports follow-on investments, funding of portfolio companies, and the ability to withstand fair-value swings in illiquid holdings over the next several quarters.
Focused Life-science StrategyA concentrated mandate in Nordic medtech, biotech and pharma creates enduring sector expertise and sourcing advantages. Active support of portfolio companies increases odds of value creation through follow-on rounds, exits and commercial scaling in a structurally growing healthcare market.
Revenue Rebound And Gross MarginA sharp 2025 revenue rebound and high gross margin indicate improving operating outcomes at underlying investments or realizations. These durable improvements can translate into better cash flow or higher realizations on exits, strengthening the investment-return engine over the medium term.